Movement Alert｜WUXI BIO Falls 5.46% in Regular Trading, Profit-Taking Follows Earlier Fresenius Deal and Citi Catalyst Watch

Market Focus

Yesterday

On November 6, WUXI BIO fell 5.46% in Regular Trading, trading at HK$46.46, with turnover of HK$326 million.

The most recent market update indicated the pullback followed short-term profit-taking after the stock had been lifted by two earlier catalysts: Citi adding WUXI BIO to its 90-day upside catalyst watch list and expectations for a possible fourth-quarter full-year guidance increase, as well as the company’s exclusive development agreement with Fresenius.

Under that agreement, Fresenius received exclusive option rights over up to 37 identified biosimilar candidates over 10 years in what has been described as the largest biosimilar development deal announced so far. The fee-for-service structure is viewed by the market as supportive of medium- to long-term order visibility. The latest market note also showed broader weakness across related names, including WUXI APPTEC, WUXI XDC and PHARMARON, suggesting sector pressure compounded the decline.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www-web.itiger.com/news/1187879412"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1187879412\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1187879412?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-11-06 09:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1187879412","market":"us","top_or_hot":-1,"title":"Movement Alert｜WUXI BIO Falls 5.46% in Regular Trading, Profit-Taking Follows Earlier Fresenius Deal and Citi Catalyst Watch","media":"Market Focus","content":"<p><p>On November 6, WUXI BIO fell 5.46% in Regular Trading, trading at HK$46.46, with turnover of HK$326 million.</p><p>The most recent market update indicated the pullback followed short-term profit-taking after the stock had been lifted by two earlier catalysts: Citi adding WUXI BIO to its 90-day upside catalyst watch list and expectations for a possible fourth-quarter full-year guidance increase, as well as the company’s exclusive development agreement with Fresenius.</p><p>Under that agreement, Fresenius received exclusive option rights over up to 37 identified biosimilar candidates over 10 years in what has been described as the largest biosimilar development deal announced so far. The fee-for-service structure is viewed by the market as supportive of medium- to long-term order visibility. The latest market note also showed broader weakness across related names, including WUXI APPTEC, WUXI XDC and PHARMARON, suggesting sector pressure compounded the decline.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜WUXI BIO Falls 5.46% in Regular Trading, Profit-Taking Follows Earlier Fresenius Deal and Citi Catalyst Watch</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜WUXI BIO Falls 5.46% in Regular Trading, Profit-Taking Follows Earlier Fresenius Deal and Citi Catalyst Watch\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-11-06 09:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On November 6, WUXI BIO fell 5.46% in Regular Trading, trading at HK$46.46, with turnover of HK$326 million.</p><p>The most recent market update indicated the pullback followed short-term profit-taking after the stock had been lifted by two earlier catalysts: Citi adding WUXI BIO to its 90-day upside catalyst watch list and expectations for a possible fourth-quarter full-year guidance increase, as well as the company’s exclusive development agreement with Fresenius.</p><p>Under that agreement, Fresenius received exclusive option rights over up to 37 identified biosimilar candidates over 10 years in what has been described as the largest biosimilar development deal announced so far. The fee-for-service structure is viewed by the market as supportive of medium- to long-term order visibility. The latest market note also showed broader weakness across related names, including WUXI APPTEC, WUXI XDC and PHARMARON, suggesting sector pressure compounded the decline.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02269","symbol_name":"药明生物","start_time":0,"source_url":"","article_id":"1187879412","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1187879412","pubTimestamp":1793928765,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On November 6, WUXI BIO fell 5.46% in Regular Trading, trading at HK$46.46, with turnover of HK$326 million.The most recent market update indicated the pullback followed short-term profit-taking...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02269":"药明生物"},"translate_title":"走势警报|药明生物常规交易下跌5.46%，早前费森尤斯交易和花旗Catalyst观察后获利了结","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02269":1},"content_text":"On November 6, WUXI BIO fell 5.46% in Regular Trading, trading at HK$46.46, with turnover of HK$326 million.The most recent market update indicated the pullback followed short-term profit-taking after the stock had been lifted by two earlier catalysts: Citi adding WUXI BIO to its 90-day upside catalyst watch list and expectations for a possible fourth-quarter full-year guidance increase, as well as the company’s exclusive development agreement with Fresenius.Under that agreement, Fresenius received exclusive option rights over up to 37 identified biosimilar candidates over 10 years in what has been described as the largest biosimilar development deal announced so far. The fee-for-service structure is viewed by the market as supportive of medium- to long-term order visibility. The latest market note also showed broader weakness across related names, including WUXI APPTEC, WUXI XDC and PHARMARON, suggesting sector pressure compounded the decline.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}